Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Developments of subunit and VLP vaccines against influenza A virus.

Deng MP, Hu ZH, Wang HL, Deng F.

Virol Sin. 2012 Jun;27(3):145-53. doi: 10.1007/s12250-012-3241-1. Epub 2012 Jun 9. Review.

PMID:
22684468
2.

Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.

Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, Chong P, Wu SC.

Vaccine. 2011 Sep 22;29(41):7163-72. doi: 10.1016/j.vaccine.2011.05.077. Epub 2011 Jun 7.

PMID:
21651946
3.

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. Epub 2011 Jan 1.

PMID:
21266846
4.
5.

Influenza virus-like particle vaccines.

Haynes JR.

Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8. Review.

PMID:
19348559
6.

Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.

Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM.

Vaccine. 2011 Aug 11;29(35):5911-8. doi: 10.1016/j.vaccine.2011.06.068. Epub 2011 Jun 30.

PMID:
21723354
7.

Research and development of universal influenza vaccines.

Du L, Zhou Y, Jiang S.

Microbes Infect. 2010 Apr;12(4):280-6. doi: 10.1016/j.micinf.2010.01.001. Epub 2010 Jan 15. Review.

PMID:
20079871
8.

Progress on adenovirus-vectored universal influenza vaccines.

Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S.

Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Review.

9.

A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK.

J Virol. 2015 Mar;89(5):2820-30. doi: 10.1128/JVI.03246-14. Epub 2014 Dec 24.

10.

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F.

MBio. 2015 Mar 10;6(2):e02556. doi: 10.1128/mBio.02556-14.

11.

New technologies for influenza vaccines.

Dormitzer PR, Tsai TF, Del Giudice G.

Hum Vaccin Immunother. 2012 Jan;8(1):45-58. doi: 10.4161/hv.8.1.18859. Epub 2012 Jan 1. Review.

PMID:
22251994
12.

Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.

Tang XC, Lu HR, Ross TM.

Viral Immunol. 2011 Aug;24(4):311-9. doi: 10.1089/vim.2011.0016.

PMID:
21830902
13.

Influenza vaccines based on virus-like particles.

Kang SM, Song JM, Quan FS, Compans RW.

Virus Res. 2009 Aug;143(2):140-6. doi: 10.1016/j.virusres.2009.04.005. Epub 2009 Apr 15. Review.

14.

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.

De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W.

Hum Vaccin Immunother. 2014;10(2):256-62. doi: 10.4161/hv.28135. Epub 2014 Feb 13. Review.

15.

Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Smith GE, Sun X, Bai Y, Liu YV, Massare MJ, Pearce MB, Belser JA, Maines TR, Creager HM, Glenn GM, Flyer D, Pushko P, Levine MZ, Tumpey TM.

Virology. 2017 Sep;509:90-97. doi: 10.1016/j.virol.2017.06.006. Epub 2017 Jun 16.

PMID:
28624679
16.

Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.

Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP.

Vaccine. 2012 May 14;30(23):3413-22. doi: 10.1016/j.vaccine.2012.03.033. Epub 2012 Mar 29.

PMID:
22465746
17.

[Research progress and prospect of universal influenza vaccine].

Luo DY, Xue CY, Cao YC.

Bing Du Xue Bao. 2013 Nov;29(6):646-50. Review. Chinese.

PMID:
24520771
18.

Advancements in the development of subunit influenza vaccines.

Zhang N, Zheng BJ, Lu L, Zhou Y, Jiang S, Du L.

Microbes Infect. 2015 Feb;17(2):123-34. doi: 10.1016/j.micinf.2014.12.006. Epub 2014 Dec 18. Review.

19.

Influenza vaccines: from whole virus preparations to recombinant protein technology.

Huber VC.

Expert Rev Vaccines. 2014 Jan;13(1):31-42. doi: 10.1586/14760584.2014.852476. Review.

PMID:
24192014
20.

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, Wang W, Wang X, Yan K, Qi X, Zhang X, Xin W, Lu Z, Li X, Bian T, Gao Y, Tan W, Ruan L.

Clin Vaccine Immunol. 2015 Jun;22(6):618-30. doi: 10.1128/CVI.00091-15. Epub 2015 Apr 1.

Supplemental Content

Support Center